Baidu
map

Moderna宣布首位患者参与其mRNA-3704治疗甲基丙二酸血症的1/2期研究

2020-02-11 不详 MedSci原创

Moderna生物技术公司宣布,首位患者入组针对MUT缺乏导致甲基丙二酸血症(MMA)的1/2期临床研究,以研究静脉输注递增剂量的mRNA-3704在MMA中的安全性和耐受性。mRNA-3704是Moderna第一个进入罕见疾病临床研究的药物。

Moderna生物技术公司宣布,首位患者入组针对MUT缺乏导致甲基丙二酸血症(MMA)的1/2期临床研究,以研究静脉输注递增剂量的mRNA-3704在MMA中的安全性和耐受性。mRNA-3704是Moderna第一个进入罕见疾病临床研究的药物。

mRNA-3704旨在指恢复导致MMA的缺失或功能失调的蛋白质。mRNA-3704由编码人类MUT(MMA患者体内缺乏的线粒体酶)的mRNA组成,并封装在Moderna专有的脂质纳米颗粒(LNP)中。临床前数据表明,mRNA-3704的重复全身给药能够在MMA小鼠模型中肝表达功能性hMUT,从而显着提高存活率和体重。重复给药并未增加肝毒性或炎症。

甲基丙二酸血症是一种罕见的,威胁生命的遗传性代谢紊乱,60%的患者是由线粒体酶甲基丙二酸CoA突变酶(MUT)缺乏引起。由于体内酸的毒性积累,这种缺乏会导致代谢危机,并且没有批准的疗法。护理标准包括饮食和姑息措施。目前,肝脏或肝肾联合移植是唯一有效的治疗方法。

mRNA-3704已被美国食品和药物管理局(FDA)授予"快速通道","孤儿药"和"罕见儿科疾病"称号,并被欧洲药品管理局(EMA)授予"孤儿"的称号。该公司计划在美国以外的地区开设多个工厂,迄今为止,已在英国获得了药品和保健产品监管机构(MHRA)的批准。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1739312, encodeId=41c61e39312bf, content=<a href='/topic/show?id=ccf169e755d' target=_blank style='color:#2F92EE;'>#甲基丙二酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69775, encryptionId=ccf169e755d, topicName=甲基丙二酸血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1abb34514844, createdName=more is better!, createdTime=Thu Dec 10 10:03:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038336, encodeId=d5142038336e0, content=<a href='/topic/show?id=77dc10129e89' target=_blank style='color:#2F92EE;'>#首位患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101297, encryptionId=77dc10129e89, topicName=首位患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Tue Mar 03 11:03:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008754, encodeId=63742008e54bd, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun May 24 15:03:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379327, encodeId=52c03e932737, content=Cash vcczxsc, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=470e5197461, createdName=1472d104m79暂无昵称, createdTime=Sun Feb 16 22:55:52 CST 2020, time=2020-02-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1739312, encodeId=41c61e39312bf, content=<a href='/topic/show?id=ccf169e755d' target=_blank style='color:#2F92EE;'>#甲基丙二酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69775, encryptionId=ccf169e755d, topicName=甲基丙二酸血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1abb34514844, createdName=more is better!, createdTime=Thu Dec 10 10:03:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038336, encodeId=d5142038336e0, content=<a href='/topic/show?id=77dc10129e89' target=_blank style='color:#2F92EE;'>#首位患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101297, encryptionId=77dc10129e89, topicName=首位患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Tue Mar 03 11:03:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008754, encodeId=63742008e54bd, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun May 24 15:03:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379327, encodeId=52c03e932737, content=Cash vcczxsc, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=470e5197461, createdName=1472d104m79暂无昵称, createdTime=Sun Feb 16 22:55:52 CST 2020, time=2020-02-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1739312, encodeId=41c61e39312bf, content=<a href='/topic/show?id=ccf169e755d' target=_blank style='color:#2F92EE;'>#甲基丙二酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69775, encryptionId=ccf169e755d, topicName=甲基丙二酸血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1abb34514844, createdName=more is better!, createdTime=Thu Dec 10 10:03:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038336, encodeId=d5142038336e0, content=<a href='/topic/show?id=77dc10129e89' target=_blank style='color:#2F92EE;'>#首位患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101297, encryptionId=77dc10129e89, topicName=首位患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Tue Mar 03 11:03:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008754, encodeId=63742008e54bd, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun May 24 15:03:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379327, encodeId=52c03e932737, content=Cash vcczxsc, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=470e5197461, createdName=1472d104m79暂无昵称, createdTime=Sun Feb 16 22:55:52 CST 2020, time=2020-02-16, status=1, ipAttribution=)]
    2020-05-24 般若傻瓜
  4. [GetPortalCommentsPageByObjectIdResponse(id=1739312, encodeId=41c61e39312bf, content=<a href='/topic/show?id=ccf169e755d' target=_blank style='color:#2F92EE;'>#甲基丙二酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69775, encryptionId=ccf169e755d, topicName=甲基丙二酸血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1abb34514844, createdName=more is better!, createdTime=Thu Dec 10 10:03:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038336, encodeId=d5142038336e0, content=<a href='/topic/show?id=77dc10129e89' target=_blank style='color:#2F92EE;'>#首位患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101297, encryptionId=77dc10129e89, topicName=首位患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Tue Mar 03 11:03:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008754, encodeId=63742008e54bd, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun May 24 15:03:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379327, encodeId=52c03e932737, content=Cash vcczxsc, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=470e5197461, createdName=1472d104m79暂无昵称, createdTime=Sun Feb 16 22:55:52 CST 2020, time=2020-02-16, status=1, ipAttribution=)]
    2020-02-16 1472d104m79暂无昵称

    Cash vcczxsc

    0

相关资讯

2019 ASCO :Moderna宣布其mRNA个体化癌症疫苗I期临床研究的中期阳性数据

生物技术公司Moderna开创了信使RNA(mRNA)疫苗,为患者创造了新一代的转化药物。今天在2019年美国临床肿瘤学会(ASCO)年会上,发表其mRNA疫苗用于切除(佐剂)和未切除(晚期)实体肿瘤患者正在进行的1期临床研究中期数据。

Moderna的mRNA纳米药物(mRNA-3927)治疗丙酸血症,获得FDA快速通道指定

Moderna公司宣布美国食品药品监督管理局(FDA)授予在研的mRNA治疗药物mRNA-3927快速通道称号,用于治疗丙酸血症(PA)。

Baidu
map
Baidu
map
Baidu
map